Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Although the main focus of immuno-oncology has been manipulating the adaptive immune system, harnessing both the innate and adaptive arms of the immune system might produce superior tumour reduction and elimination. Tumour-associated macrophages often have net pro-tumour effects, but their embedded location and their untapped potential provide impetus to discover strategies to turn them against tumours. Strategies that deplete (anti-CSF-1 antibodies and CSF-1R inhibition) or stimulate (agonistic anti-CD40 or inhibitory anti-CD47 antibodies) tumour-associated macrophages have had some success. We hypothesized that pharmacologic modulation of macrophage phenotype could produce an anti-tumour effect. We previously reported that a first-in-class selective class IIa histone deacetylase (HDAC) inhibitor, TMP195, influenced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro. Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatment alters the tumour microenvironment and reduces tumour burden and pulmonary metastases by modulating macrophage phenotypes. TMP195 induces the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumours. Furthermore, combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade in this model significantly enhances the durability of tumour reduction. These data introduce class IIa HDAC inhibition as a means to harness the anti-tumour potential of macrophages to enhance cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone deacetylase inhibitor, TMP195, polarizes TAMs toward an anti‐tumor phenotype and increases the efficacy of carboplatin, paclitaxel, and anti‐PD‐1 therapies [84].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
The Immunological Genome Project: networks of gene expression in immune cells
The Immunological Genome Project Consortium, Heng, T. S. P., Painter, M. W., Elpek, K., Lukacs-Kornek, V., Mauermann, N., Turley, S. J., Koller, D., Kim, F. S., Wagers, A. J., et al. (2008) · Nature Immunology · doi:10.1038/ni1008-1091 · Cited by 1,864
Self-citation
Research works printed but not linked: 2
- DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL & Coussens LM Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery 1, 54– 67, 10.1158/2159-8274.cd-10-0028 (2011). 22039576 PMC3203524 · DOI · Paper page
- Malhotra D, Fletcher AL, Astarita J, Lukacs-Kornek V, Tayalia P, Gonzalez SF, Elpek KG, Chang SK, Knoblich K, Hemler ME, Brenner MB, Carroll MC, Mooney DJ, Turley SJ & Immunological Genome Project C Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nature immunology 13, 499– 510, 10.1038/ni.2262 (2012). 22466668 PMC3366863 · DOI · Paper page
Cited by
Items 401–500 of 568
Ghosh, R., Bhowmik, A., Biswas, S., Samanta, P., Sarkar, R., Pakhira, S., Mondal, M., Hajra, S., & Saha, P. (2025) · Molecular Medicine · doi:10.1186/s10020-024-01032-1 · Cited by 10
“CD44 + /CD133 + cells were isolated using MACS LS column (Miltenyi Biotec, USA) after leveled with CD44 and CD133 antibody conjugated with microbeads (Miltenyi Biotec, USA) by following manufacture’s protocol and subjected to further analysis.”
InfluentialZhang, N., Lu, Q., Xu, C., Duan, F., Ma, Y., Zhou, L., Zhang, Y., Ma, Y., Lin, Q., & Lu, K. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123390 · Cited by 7
Beyond polarization: macrophage senescence in immunoregulation and cancer therapy
Mei, S., Zhang, L., Dai, X., Ji, S., Shen, J., & He, W. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.115921 · Cited by 8
“Reports indicate that selective class IIa HDAC inhibitors can influence the macrophage phenotype, resulting in decreased tumor burden and increased survival rates in mouse models of breast cancer [135].”
Turkman, N., Xu, S., Huang, C.-H., Eyermann, C. E., Salino, J., & Khan, P. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02064 · Cited by 8
Modulating cell differentiation in cancer models
Fulghieri, P., Stivala, L. A., & Sottile, V. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210230 · Cited by 7
Yuan, W., Hai, B., Ren, X., Zhu, J., Zhang, C., Guan, Z., Jia, J., Wang, H., Cao, B., & Song, C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100867 · Cited by 8
Determinants, mechanisms, and functional outcomes of myeloid cell diversity in cancer
Caronni, N., Montaldo, E., Mezzanzanica, L., Cilenti, F., Genua, M., & Ostuni, R. (2021) · Immunological Reviews · doi:10.1111/imr.12944 · Cited by 6
Global hotspots and trends in pre-metastatic niche research: a bibliometric analysis(2005-2024)
Cheng, M., Sun, Q., Duan, H., & Chen, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1552053 · Cited by 9
Immune microenvironment regulation and clinical immunotherapy strategies of metastatic liver cancer
Liu, D., Li, M., Liang, Y., Xu, F., Li, R., & Sun, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1633315 · Cited by 10
He, M., Peng, Q., Yang, Q., Guan, X., Liu, Q., Chen, R., Zhou, D., Wang, L., Zhang, Y., Li, S., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114497 · Cited by 7
Tatárová, Z., Blumberg, D. C., Bensen, A. L., Mills, G. B., & Jonas, O. H. (2023) · Cells · doi:10.3390/cells12020308 · Cited by 7
“The mechanisms underlying PD-L1 upregulation are broad and complex, and thus it is not surprising that IHC-based measurements are difficult to interpret and are often inadequate [66].”
BackgroundResultInfluentialChen, X., Ding, X., Fang, J., Mao, C., Gong, X., Zhang, Y., Zhang, N., Yan, F., Lou, Y., Chen, Z., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01438 · Cited by 7
Fu, Q., Lu, Z., Chang, Y., Jin, T., & Zhang, M. (2024) · Industrial Crops and Products · doi:10.1016/j.indcrop.2024.119589 · Cited by 6
Improving TRAIL-induced apoptosis in cancers by interfering with histone modifications
Zhang, B., Chen, D., Dekker, F. J., & Quax, W. J. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.58 · Cited by 6
“TMP-195 Class IIa HDAC Breast tumour([74])”
Zhang, Y., LIM, D. J., Cai, Z., Peng, J., Jia, B., Chu, G., Zhang, F., Dong, C., & Feng, Z. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113779 · Cited by 6
Selective Inhibition of Histone Deacetylase Class IIa With MC1568 Ameliorates Podocyte Injury
He, X., Sun, T., Zhang, P., Xia, Z., Gao, C., Ren, H., & Ji, D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.848938 · Cited by 6
“HDAC IIa composes of HDAC4, HDAC5, HDAC7, and HDAC9, numbers of studies demonstrated HDAC IIa inhibition as an alternative approach to avoid the progression of various diseases, examples like breast tumors (18), pancreatic cancer (19), multiple myeloma (20), and type 2 diabetes (21).”
BackgroundLiu, H., Zhang, F., Wang, K., Tang, X., & Wu, R. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp02261a · Cited by 6
Dent, P., Booth, L. A., & Poklepovic, A. S. (2019) · Immunometabolism · doi:10.20900/immunometab20200002 · Cited by 6
“In general, HDAC inhibitors are viewed as acting in a positive fashion, increasing the activity of immune cells, including T cells and macrophages [35,36].”
BackgroundLiu, J., Deng, Y., Liu, Z., Li, X., Zhang, M., Yu, X., Liu, T., Chen, K., & Li, Z. (2023) · Medicina · doi:10.3390/medicina59071285 · Cited by 6
“The selective Class IIa Histone Deacetylase 2 (HDAC2) inhibitor TMP195 has been shown to convert TAMs to an M1-like macrophage phenotype and therefore has demonstrated impressive efficacy, especially in combination with paclitaxel [29].”
BackgroundLiu, J., Wu, M., Lyu, Q., Yang, C., Fan, N., Chen, K., & Wang, W. (2025) · Advanced Science · doi:10.1002/advs.202415684 · Cited by 9
Albini, A., Trapani, D., Bertolini, F., Noonan, D. M., Orecchia, R., & Corso, G. (2025) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-24-0558 · Cited by 9
“Reprogramming TAMs toward the M1 phenotype is under investigation as a therapeutic strategy (89, 90).”
Pedroza, D. A., Yuan, X., Liu, F., Chan, H. L., Zhang, C., Bowie, W., Smith, A. J., Calderon, S. J., Lieu, N., Wu, W., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-67964-2 · Cited by 12
“These include macrophage reprogramming, using Class II HDAC inhibition 12 and the LPS derivate, monophosphoryl lipid A+INFy 13 , phagocytic reactivation by CD47/SIRPalpha blockade with an anti-CD47 antibody 14 , and recruitment inhibition or depletion by both small molecule and antibody based…”
miRNome targeting NF-κB signaling orchestrates macrophage-triggered cancer metastasis and recurrence
Chen, D., Wang, J., Liu, Z., Li, P.-L., Chan, K., Wu, X.-N., Yao, W., Yao, T., Kuang, D., & Yuan, W. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.009 · Cited by 6
Downregulation of IRF8 in alveolar macrophages by G-CSF promotes metastatic tumor progression
Tzetzo, S. L., Kramer, E. D., Mohammadpour, H., Kim, M., Rosario, S. R., Yu, H., Dolan, M., Oturkar, C. C., Morreale, B. G., Bogner, P. N., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109187 · Cited by 5
Functional Evaluation of KEL as an Oncogenic Gene in the Progression of Acute Erythroleukemia
Liu, W., Wu, Z., Yu, Y., Qiao, C., Zhu, H., Hong, M., Zhu, Y., Qian, S., Chen, S., Wu, D., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5885342 · Cited by 6
Duan, W. H., Jin, L. Y., Cai, Z. C., LIM, D. J., & Feng, Z. H. (2021) · PubMed · doi:10.3967/bes2021.097 · Cited by 6
“Immunofluorescence method is detailed elsewhere([26]).”
BackgroundMethodInfluentialCaspase Inhibition Modulates Monocyte-Derived Macrophage Polarization in Damaged Tissues
Solier, S., Mondini, M., Meziani, L., Jacquel, A., Lacout, C., Berghe, T. V., Julé, Y., Martinou, J., Pierron, G., Rivière, J., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044151 · Cited by 4
“Pan-caspase inhibition thus appears as an alternative strategy to monoclonal antibodies and small molecule inhibitors of CSF1 and CSF1R [10,62], STAT3 inhibitory molecules [63], DNA vaccine against the “M2”-associated asparaginyl endopeptidase legumain [64] and other strategies [65] to modulate the polarization of mac…”
BackgroundGu, J., Wang, J., Sun, Y., Mao, X., Qian, C., Tang, X., Ji, W., Xie, H., Ling, L., Zhao, Y., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6864 · Cited by 4
Structure-Based Identification of Novel Histone Deacetylase 4 (HDAC4) Inhibitors
Agarwal, R., Pattarawat, P., Duff, M. R., Wang, H. R., Baudry, J. Y., & Smith, J. C. (2024) · Pharmaceuticals · doi:10.3390/ph17070867 · Cited by 5
Breast Cancer Immunity: It is TIME for the Next Chapter
Quail, D. F., Park, M., Welm, A. L., & Ekiz, H. A. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041324 · Cited by 7
Long-range action of an HDAC inhibitor treats chronic pain in a spared nerve injury rat modelPreprint
Centeno, M. V., Alam†, M. S., Haldar, K., & Apkarian, A. V. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.13.571583 · Cited by 5
Khandelwal, A., Fathi, A. H., Shetty, S., Mukhopadhyay, A., Devi, V., & Kabekkodu, S. P. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03995-5 · Cited by 5
Wheeler, C. E., & Lamouille, S. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.124084 · Cited by 4
Targeting AKR1B1 reprograms tumor-associated macrophages to enhance antitumor immunity
Liu, Y., Zhou, C., Tang, Y., Lei, H., Aihemaiti, A., Liu, H., Zou, P., Xie, J., Guo, X., Xia, R., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014043 · Cited by 7
“All the cells were authenticated by short tandem repeat analysis and tested for Mycoplasma contamination annually using mycoBlue Mycoplasma detector (D101, Vazyme) according to the manufacturer’s instructions.”
Leveraging macrophage plasticity for precision-targeted tumor immunotherapy
Li, S., Wang, X., Li, L., Chen, L., & Sun, Z.-J. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168176 · Cited by 9
Duan, X., Yeerkenbieke, G., Feng, Y., Zhou, M., Zhang, Y., Zhou, J., & Li, J. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-1073 · Cited by 5
PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer
Liu, F., Liu, W., Tan, Y., Shang, Y., Ling, S., Jiang, X., Zhang, Z., Sun, S., & Xie, P. (2025) · Oncogene · doi:10.1038/s41388-025-03468-z · Cited by 6
“We noticed that the phosphorylation of Rb, initially reduced by palbociclib treatment, recovered after prolonged drug exposure, which indicated adaptive resistance was occurred (Fig.”
Zhang, W., He, T., Fang, K., Gao, Y., Sun, Y., Nan, F., Ding, J., Chen, Y., & Fang, Y. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01646-z · Cited by 5
Sinha, R., Dvorak, M., Ganesan, A., Kalesinskas, L., Niemeyer, C. M., Flotho, C., Sakamoto, K. M., Lacayo, N. J., Patil, R. V., Perriman, R., et al. (2023) · Cancers · doi:10.3390/cancers15215204 · Cited by 4
“We also note that TMP195, a first-in-class highly selective class II HDAC inhibitor, has shown potent activity in breast cancer mouse model studies [70], making it an attractive candidate to test in JMML patients who display increased HDAC5 and HDAC9 activity.”
BackgroundSenhorello, I. L. S., Matiz, O. R. S., Canavari, I. C., Hernandez, G. V., Anai, L. A., Ampuero, R. A. N., Pazzini, J. M., Prado, C. M., Meirelles, F. V., Vasconcelos, R. D. O., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1257932 · Cited by 5
Centeno, M. V., Alam†, M. S., Haldar, K., & Apkarian, A. V. (2025) · Journal of Pain · doi:10.1016/j.jpain.2025.105396 · Cited by 8
Patysheva, M. R., Stakheyeva, M. N., Larionova, I., Fedorov, A. A., Kzhyshkowska, J. G., & Чердынцева, Н. В. (2019) · Experimental Oncology · doi:10.32471/exp-oncology.2312-8852.vol-41-no-3.13597 · Cited by 5
Harnessing class II histone deacetylases in macrophages to combat breast cancer
Reichman, H., & Munitz, A. (2017) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.32 · Cited by 5
An epigenetic modifier triggers therapeutic immune responses against breast cancer
Galluzzi, L., & Kroemer, G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1313376 · Cited by 4
“PD-1) against endogenous MMTV-PyMT-driven mammary carcinomas.(9) These data suggest that TMP195 mediates anti-”
BackgroundInfluentialWang, J., Li, H., Gao, M., Xie, Y., Zhu, G., Qian, Y., Lin, J., & Li, C. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202510738 · Cited by 3
Gül, S., Vergnaud, J., Fay, F., & Fattal, E. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01970-1 · Cited by 4
“…modifications should be designed and Epigenetic regulation of macrophages has been investigated through the mediation of histone deacetylases [93, 94], histone methyltransferases, or histone demethylases [94], with several current clinical trials evaluating the potential of combining…”
Xu, S., Huang, C.-H., Eyermann, C. E., Georgakis, G. V., & Turkman, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-65668-z · Cited by 3
“We performed a structure–activity relationship (SAR) study using TMP195 as a lead inhibitor and we successfully identified new tracer candidates with IC 50 in the low nM range for class-IIa HDAC4 and 5 (IC 50 < 20 nM), and low potency (IC 50 > 500 nM) to class-I/IIb HDAC isoforms 23 .”
Histone deacetylase 7 mediates lipopolysaccharide-inducible mitochondrial fission in macrophages
Abrol, R., Afroz, S. F., Curson, J. E. B., Raven, K. D., Gupta, K. D., Gunther, K. S., Jones, A., Reid, R. C., Xiong, Z., Gunter, J. H., et al. (2025) · Journal of Cell Science · doi:10.1242/jcs.264376 · Cited by 4
“Interestingly however, TMP195, a pharmacological inhibitor of class IIa HDACs (Guerriero et al., 2017), attenuated LPS-inducible fission in mouse BMMs (Fig.”
InfluentialHarnessing the Tumor Microenvironment for the Treatment of Double Hit Lymphoma
Lossos, C., Liu, Y., Christie, A. L., Hemann, M. T., & Weinstock, D. M. (2016) · Blood · doi:10.1182/blood.v128.22.47.47 · Cited by 3
Dang, Z., Li, H., Xue, S., Shao, B., Ning, Y., Su, G., Zhang, F., Yu, W., & Leng, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116396 · Cited by 4
Villanueva, M. T. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.82 · Cited by 3
Therapeutic Breast Reconstruction Using Gene Therapy–Delivered IFNγ Immunotherapy
Davis, C. R., Than, P. A., Khong, S. M. L., Rodrigues, M., Findlay, M. W., Navarrete, D. J., Ghali, S., Vaidya, J. S., & Gurtner, G. C. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0315 · Cited by 3
“This mechanism is consistent with proposed therapeutic pathways of IFNg andmacrophages (5, 6, 24).”
Rel-ating myeloid cells to cancer therapy
Takahashi, H., & Varner, J. A. (2020) · Nature Cancer · doi:10.1038/s43018-020-0069-8 · Cited by 4
Peng, J., Cai, Z., Zhao, R., Chen, J., Liu, G., Dong, C., LIM, D. J., & Feng, Z. (2020) · Toxicology Research · doi:10.1093/toxres/tfaa069 · Cited by 3
Hasan, A. U., Sato, S., Obara, M., Kondo, Y., & Taira, E. (2025) · Medicines · doi:10.3390/medicines12040026 · Cited by 2
“Of particular interest, TMP-195 generally exhibits a lack of direct overt cytotoxicity across various cell lines, including breast cancer cells and neonatal rat ventricular myocytes (NRVMs) [41,42].”
Differential transcriptomic modulation by histone deacetylase inhibitor SAHA in LUAD and LUSC
Wang, F., Yang, Q., Shu, L., Cen, H., Huang, Y., Ma, X., Lin, Y., Guan, X., Wang, C., Fu, X., et al. (2026) · Clinical Epigenetics · doi:10.1186/s13148-026-02051-x · Cited by 2
“In lung cancer specifically, aberrant HDAC expression has been linked to increased proliferation, invasion, epithelial–mesenchymal transition and resistance to chemotherapy or targeted agents, underscoring HDACs as central nodes in NSCLC patho-biology and attractive therapeutic targets [15–17].”
Histone epigenetic modifications and their relationship with cancer: a comparative medicine view
Senhorello, I. L. S., & Tinucci‐Costa, M. (2023) · Ciência Rural · doi:10.1590/0103-8478cr20220510 · Cited by 4
Unlocking Macrophage Secrets: Histone Deacetylases in Chronic Transplant Rejection
Hałasa, M., & Wawruszak, A. (2024) · Results and problems in cell differentiation · doi:10.1007/978-3-031-65944-7_12 · Cited by 2
Down-regulating HDAC2-LTA4H pathway ameliorates renal ischemia-reperfusion injury
Ye, K., Li, J., Huo, Z., Xu, J., Dai, Q., Qiao, K., Cao, Y., Yan, L., Liu, W., Hu, Y., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167889 · Cited by 2
Bacterium‐Inspired Nanoagents Armed with On‐Switch of Immune Recruitment and Immune Activation
Li, C., Zhang, Y., Qi, Y., Liu, M., Li, B., Zhang, M., Feng, J. X., & Zhang, X. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000231 · Cited by 2
mPPTMP195 nanoparticles enhance fracture recovery through HDAC4 nuclear translocation inhibition
Chen, X., Li, C., Zhao, J., Liu, Y., Zhao, Z., Wang, Z., Li, Y., Wang, Y., Guo, L., Lu, L., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02436-1 · Cited by 2
Tatárová, Z., Blumberg, D. C., Korkola, J. E., Heiser, L. M., Muschler, J. L., Schedin, P. J., Ahn, S. W., Mills, G. B., Coussens, L. M., Jonas, O. H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.01.458631 · Cited by 2
“Recruitment of CSF1R+ cells at a late time point indicatings sequential or alternating administration of HDAC inhibitors with CSF1/CSF1R targeting agents may be efficacious while simultaneous dosing is not (Guerriero et al., 2017)) (Figure 4C and S8).”
BackgroundResultInfluentialFunctional Evaluation of KEL as an Oncogenic Gene in the Progression of Acute ErythroleukemiaPreprint
Wu, Z., Liu, W., Yu, Y., Qiao, C., Zhu, H., Hong, M., Zhu, Y., Qian, S., Chen, S., Wu, D., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-381817/v2 · Cited by 2
Selective class IIa HDAC inhibition reverses diastolic dysfunction in cardiometabolic HFpEFPreprint
Huang, J., Schreiter, F. C., Fan, J., Chen, Z., Paluvai, H., Withaar, C., Oeing, C. U., Saadatmand, A. R., Schoger, E., Haydar, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.14.699428 · Cited by 2
Self-citationElghetany, M. T., Pan, J.-L., Sekar, K., Major, A. M., Su, J. M. F., Adesina, A. M., Hui, K. M., Li, X., & Teo, W. (2024) · iScience · doi:10.1016/j.isci.2024.110932 · Cited by 1
MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer
Park, J., Chen, Y.-Y., Cao, J. J., An, J., Yen, R.-W. C., Outen, J. D., Baylin, S. B., & Topper, M. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115722 · Cited by 2
Tolotto, V., Gualandi, N., Cortolezzis, Y., Picco, R., Colitti, M., D’Este, F., Gani, M., Hancock, W. W., Terrosu, G., Degrassi, C., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70152 · Cited by 3
“Trifluoromethyloxadiazole-based compounds [72] proved efficacy in boosting anticancer immunity in CRC [73], similarly to what reported by original developers in breast cancer [74], but had limited efficacy on tumor cells [34], as well as putative nonspe-cific effects [75].”
Nanomedicines targeting myeloid cells for breast cancer therapy
Deng, X., Liang, Y., Xu, X., & Saw, P. E. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100038 · Cited by 1
Wang, Y., Ramnath, D., Gupta, K. D., Prakrithi, P., Bisht, K., Miller, G. C., Xiong, Z., Wan, Y., Tejo, E. N., Curson, J. E. B., et al. (2026) · Clinical & Translational Immunology · doi:10.1002/cti2.70100 · Cited by 1
“Thus, it will be of interest in the future to evaluate whether small molecule inhibitors of class IIa HDACs 65,66 can attenuate dysregulated metabolism, chronic inflammation and/or liver fibrosis in mouse models of obesity-driven CLD.”
Ye, J., Deng, Y., Zhang, B., Li, C., Guo, X., Yue, R., Wan, H., Hao, Y., & Xiao, S. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02121-5 · Cited by 2
Le, T. V., Deviatiiarov, R. M., Tomoyoshi, Y., Gusev, O., Dubovskova, S., Nguyen, N.-L. T., Hanayama, R., & Nguyen, T. D. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154245 · Cited by 1
Khalaj, M., Burden, A. T., Gutierrez, M. L., Hoonsbeen, S. C., Nejad, P., Raveh, T., Young, J. S., Fattahi, F., & Weissman, I. L. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0506 · Cited by 4
Immune Cells As Targets and Tools For Cancer Therapy
Tonecka, K., Pilch, Z., Ramji, K., Taciak, B., Kiraga, Ł., Król, M., & Rygiel, T. P. (2017) · Immunotherapy Open Access · doi:10.4172/2471-9552.1000143 · Cited by 1
Intrinsic and acquired cancer immunotherapy resistance
Saleh, R., Nair, V. S., Toor, S. M., & Elkord, E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823397-9.00014-4 · Cited by 2
Role of macrophages in tumor development
Karim, M. R., Hossain, D., Uddin, A. M., & Rume, F. I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822368-0.00007-4 · Cited by 3
Hasan, N., Hasani, N. A. H., Omar, E., Sham, F. R., Fuad, S. B. S. A., Karim, M. K. A., & Ibahim, M. J. (2023) · Cancer Biomarkers · doi:10.3233/cbm-220268 · Cited by 1
“The role of immune system in the regulation of tumour control has been elucidated [9,10].”
Epigenetic Regulation in Breast Cancer Tumor Microenvironment
Kaur, B., Mondal, P., & Meeran, S. M. (2023) · Epigenetics and human health · doi:10.1007/978-3-031-42365-9_6 · Cited by 2
Hsu, K., Huang, Y., Chu, J.-C., Huang, Y.-W., Hu, J., Lin, T. E., Yen, S., Weng, J.-R., & Huang, W.-J. (2024) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2024.2406025 · Cited by 1
Miyahira, A. K., Sharifi, M. N., Chesner, L. N., El-Kenawi, A., Haas, R., Sena, L. A., Tewari, A. K., Pienta, K. J., & Soule, H. R. (2024) · The Prostate · doi:10.1002/pros.24826 · Cited by 1
Acral melanoma: Molecular subtyping as a gateway to precision medicine
Dika, E., & Magnaterra, E. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20736 · Cited by 1
Role of Tumour-Associated Macrophages in Colon Cancer Progression and Its Therapeutic Targeting
Mehta, A., Soni, V. K., Ratre, Y. K., Amit, A., Shukla, D., Kumar, A., & Vishvakarma, N. K. (2022) · Springer eBooks · doi:10.1007/978-3-030-72702-4_10 · Cited by 1
Functional Evaluation of KEL As An Oncogenic Gene in The Progression of Acute ErythroleukemiaPreprint
Wu, Z., Liu, W., Yu, Y., Qiao, C., Zhu, H., Hong, M., Zhu, Y., Qian, S., Chen, S., Wu, D., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-381817/v1 · Cited by 1
Zhang, P., Du, Y., Bai, H., Wang, Z., Duan, J., Wang, X., Zhong, J. Y., Wan, R., Xu, J., He, X., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1331646/v1 · Cited by 1
Li, S., Zhao, F., Zhu, M.-X., Zhao, W., Xie, R.-X., Shi, H., & Li, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1469920/v2 · Cited by 1
Harnessing Mechanical Forces for Cancer TreatmentPreprint
Kumari, A., Veena, S., Luha, R., & Tijore, A. (2023) · Preprints.org · doi:10.20944/preprints202307.2038.v1
LRH-1 is a novel regulator of neutrophil-driven immune responses within the tumor microenvironmentPreprint
Wang, Y., Duong, B., Keeley, S., Krawczynska, N., Bendre, S. V., Schane, C. P., Weisser, E., Cobo-Vuilleumier, N., Kockaya, L. I., Fei, Y.-F., et al. (2025) · bioRxiv · doi:10.1101/2025.09.16.676030
Papers of note in Nature 543 (7645)
VanHook, A. M. (2017) · Science Signaling · doi:10.1126/scisignal.aan2406
How cancers usurp macrophages to keep growing
Sonzogni, O., & Wulf, G. M. (2019) · Cell Research · doi:10.1038/s41422-019-0172-5
Calin, G., Hofman, P. M., & Mani, S. A. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-452-5
Macrophages and pathophysiology of bone cancers
Sousa, S., & Määttä, J. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00056-6
Polymeric Nanoparticles-Based Drug and Gene Delivery to Macrophages
Sahle, F. F. (2022) · Springer eBooks · doi:10.1007/978-3-030-84164-5_7
Significance of Tumor-Associated Macrophages in the Clinical Therapy of Breast Cancer
(2022) · Journal of Contemporary Medical Practice · doi:10.53469/jcmp.2022.04(02).02
Ye, J., Zhong, S., Deng, Y., Yao, X., Liu, Q., Wang, J., & Xiao, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1462010/v1
Li, S., Zhao, F., Zhu, M.-X., Zhao, W., Xie, R.-X., Shi, H., & Li, J.-Z. (2022) · Research Square · doi:10.21203/rs.3.rs-1469920/v1
Asad, S., Damicis, A., Heng, Y. J., Kananen, K., Collier, K. A., Adams, E., Kensler, K. H., Baker, G. M., Wesolowski, R., Sardesai, S. D., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1598621/v1
Wiersinga, W. J., & Haak, B. W. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734920969.793556473
Faculty Opinions recommendation of Cellular backpacks for macrophage immunotherapy.
Young, H. A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737846681.793575657
Local Delivery of Minocycline and Vorinostat Act Synergistically to Inhibit Recurrence of GliomasPreprint
Zhao, G., Jia, J., Wang, L., Zhang, Y., Yang, H. E., Yang, L., Yu, R., Liu, H., & Zhu, Y. (2020) · doi:10.21203/rs.3.rs-33885/v1
Turkman, N., Xu, S., Huang, C.-H., Eyermann, C. E., Salino, J., & Khan, P. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.12.516260
“We then investigated whether the nonradioactive 4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoic acid (1) can inhibit HDACs using the cell-based assay similar to our previous report (28).”
MethodJiang, J., & Lü, H. (2022) · Research Square · doi:10.21203/rs.3.rs-2201390/v1
Metadata
- Authors
- Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., Davis, S. P., Lobera, M., Nolan, M. A., & Letai, A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Nolan, Michael A.
- Letai, Anthony
- ORCID
- Venue
- Nature
- Published
- 2017-03
- Volume
- 543
- Issue
- 7645
- Pages
- 428-432
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8170529
- OpenAlex
- W2591627715
- Cited by
- 558
- References
- 35
- Citations by year
- 2026: 35 · 2025: 51 · 2024: 51 · 2023: 63 · 2022: 74 · 2021: 94 · 2020: 68 · 2019: 63 · 2018: 33 · 2017: 25
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA205967, F32CA180733)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- breast cancer, tumour-associated macrophages, antitumor immunity, tumor microenvironment, lung metastasis, chemotherapy synergy, T cell checkpoint blockade, CSF-1
- MeSH terms
- Animals, Benzamides, Breast Neoplasms, Cell Differentiation, Disease Models, Animal, Drug Synergism, Female, Humans, Lung Neoplasms, Macrophage Activation, Macrophages, Oxadiazoles, Phagocytosis, Cell Line, Tumor, Tumor Burden, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.